Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus bevacizumab or chemotherapy in PD-1–pretreated non-squamous NSCLC
ChiCTR2500105769Phase 4Not yet recruiting
- Sponsor
- Yancheng Third People's Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of QL1706 in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Yancheng Third People's Hospital. Primary endpoints: Progression-free survival and Safety. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2500105769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105769.